News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
623,434 Results
Type
Article (44832)
Company Profile (128)
Press Release (578474)
Section
Business (171597)
Career Advice (1696)
Deals (31802)
Drug Delivery (109)
Drug Development (79182)
Employer Resources (95)
FDA (16684)
Job Trends (13644)
News (307903)
Policy (33792)
Tag
Academia (2560)
Alliances (44455)
Alzheimer's disease (1380)
Antibody-drug conjugate (ADC) (126)
Approvals (16642)
Artificial intelligence (220)
Bankruptcy (293)
Best Places to Work (11204)
Breast cancer (245)
Cancer (1781)
Cardiovascular disease (140)
Career advice (1385)
CAR-T (127)
Cell therapy (358)
Clinical research (63906)
Collaboration (694)
Compensation (348)
COVID-19 (2446)
C-suite (171)
Data (1676)
Diabetes (233)
Diagnostics (6078)
Earnings (67064)
Events (97979)
Executive appointments (557)
FDA (17652)
Funding (585)
Gene therapy (245)
GLP-1 (738)
Government (4535)
Healthcare (18545)
Infectious disease (2558)
Inflammatory bowel disease (127)
Interviews (305)
IPO (15190)
Job creations (2873)
Job search strategy (1180)
Layoffs (410)
Legal (7351)
Lung cancer (256)
Manufacturing (242)
Medical device (12609)
Medtech (12614)
Mergers & acquisitions (17020)
Metabolic disorders (619)
Neuroscience (1827)
NextGen: Class of 2025 (6254)
Non-profit (4350)
Northern California (2135)
Obesity (340)
Opinion (238)
Patents (171)
People (49723)
Phase I (19565)
Phase II (27932)
Phase III (21324)
Pipeline (769)
Postmarket research (2871)
Preclinical (8253)
Radiopharmaceuticals (240)
Rare diseases (343)
Real estate (4657)
Regulatory (23768)
Research institute (2312)
Resumes & cover letters (297)
Southern California (1808)
Startups (3093)
United States (18468)
Vaccines (549)
Weight loss (256)
Date
Today (9)
Last 7 days (817)
Last 30 days (2602)
Last 365 days (33935)
2025 (5229)
2024 (34854)
2023 (39702)
2022 (49946)
2021 (54073)
2020 (52688)
2019 (45675)
2018 (34617)
2017 (31644)
2016 (29849)
2015 (34515)
2014 (25624)
2013 (21107)
2012 (22664)
2011 (23967)
2010 (21620)
Location
Africa (716)
Arizona (128)
Asia (37357)
Australia (6195)
California (4775)
Canada (1705)
China (410)
Colorado (225)
Connecticut (232)
Europe (84905)
Florida (716)
Georgia (170)
Illinois (450)
Indiana (253)
Japan (128)
Maryland (750)
Massachusetts (3631)
Michigan (195)
Minnesota (312)
New Jersey (1378)
New York (1386)
North Carolina (866)
Northern California (2135)
Ohio (168)
Pennsylvania (1079)
South America (990)
Southern California (1808)
Texas (676)
Utah (149)
Washington State (436)
623,434 Results for "drug information association".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam.
February 28, 2025
·
2 min read
·
Tristan Manalac
IRA
Drug Pricing and the Uncertain Future of the IRA Under Trump
While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug prices in the U.S., Trump has so far been mum on how the controversial law could evolve in the coming years.
January 31, 2025
·
4 min read
·
Jef Akst
Depression
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study
After SPN-820’s failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s therapy Onapgo to sustain the company.
February 20, 2025
·
2 min read
·
Tristan Manalac
Lone Star Bio
The Foundation for Angelman Syndrome Therapeutics (FAST) announces the establishment of an associated drug development accelerator
The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS2Bio Inc.
June 4, 2024
·
3 min read
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
·
1 min read
·
Annalee Armstrong
BioMidwest
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
Telomir Pharmaceuticals, Inc. announced that its scientific advisor, Adam Kaplin, M.D., Ph.D., was invited by InSilicoTrials to speak on its panel discussion on June 17, 2024, at the DIA Global Annual Meeting.
June 17, 2024
·
4 min read
Multiple sclerosis
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since December 1996 and six patient deaths.
January 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
November 27, 2024
·
7 min read
Policy
Association for Diagnostics & Laboratory Medicine (formerly AACC) survey finds that FDA’s final laboratory developed tests rule will impede the fight against the U.S.'s drug epidemic
The Association for Diagnostics & Laboratory Medicine released the results of a survey that ADLM conducted to determine how the Food and Drug Administration’s final laboratory developed tests rule will impact patient access to essential tests.
June 25, 2024
·
4 min read
Podcast
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron sues Sanofi over an alleged failure to provide adequate information about Dupixent sales.
February 12, 2025
·
1 min read
·
Heather McKenzie
1 of 62,344
Next
